Frankfurt - Delayed Quote EUR

Achieve Life Sciences, Inc. (SP4P.F)

3.0450

+0.0150

+(0.50%)

At close: January 31 at 8:06:30 AM GMT+1

Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory

We came across a bullish thesis on Achieve Life Sciences, Inc. (ACHV) on Substack by Jacob Rowe. In this article, we will summarize the bulls’ thesis on ACHV. Achieve Life Sciences, Inc. (ACHV)’s share was trading at $3 as of Jan 23rd. Achieve Life Sciences (ACHV) presents a compelling investment opportunity, with its nicotine cessation drug, Cytisinicline, […]

Insider Monkey 7 days ago

ACHV
ACHV: Long-Term Exposure Requirement Complete

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Update for 2025 Achieve Life Sciences, Inc. (NASDAQ:ACHV) has been busy since its previous quarterly update, adding new board members and executives and completing the long-term portion of its ORCA OL study which will generate critical safety data to be used in the new drug application (NDA) for smoking cessation. The

Zacks Small Cap Research 11 days ago

ACHV
Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

New Directors Bring Extensive Leadership Experience in Corporate Strategy and CommercializationSEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Kristen Slaoui, Ph.D., and Nancy Phelan will join its Board of Directors. Achieve also announced that current

GlobeNewswire 21 days ago

ACHV
Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement for NDA Submission ORCA-OL Long-Term Exposure Timelines Remain on Track with No Safety Concerns Identified Planned Cytisinicline NDA Submission on Target for Q2 2025 SEATTLE and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the global dev

GlobeNewswire 24 days ago

ACHV
Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

SEATTLE and VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the development and commercialization of cytisinicline for nicotine dependence, announced today that the company will be hosting in-person one-on-one meetings coinciding with the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, January 13-16, 2025. Rick Stewart, Chief Executive Officer of Achieve, along with other mem

GlobeNewswire 25 days ago

ACHV
Should You Expect a Strong Re-rating for Achieve Life Sciences (ACHV) Post Results in Q1?

Rogue Funds, an investment management company, released its third quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund returned -3.03% net of fees in the quarter. The fund faced a slight decline in the value of the portfolio, which was quite disappointing. Two of the fund’s core positions fell […]

Insider Monkey 29 days ago

ACHV
Institutional shareholders may be less affected by Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) pullback last week after a year of 0.5% returns

Key Insights Given the large stake in the stock by institutions, Achieve Life Sciences' stock price might be vulnerable...

Simply Wall St. last month

ACHV
Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

SEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced that Mark Oki has joined the company as its Chief Financial Officer, effective December 5, 2024. Mr. Oki will oversee the company's financial strategy and operations, including accounting, investor relations, inf

GlobeNewswire last month

ACHV
Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

Milestone Reinforces the Potential for Cytisinicline as a First-in-Class Treatment for Vaping CessationSEATTLE and VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the development and commercialization of cytisinicline for nicotine dependence, announced today the successful outcome of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). This meeting represents a key mi

GlobeNewswire last month

ACHV
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

SEATTLE and VANCOUVER, British Columbia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced that Rick Stewart, CEO of Achieve Life Sciences, and management will be participating at two upcoming investor conferences. Meetings will be conducted at the Jefferies London Healthcare Conference on November 19-

GlobeNewswire 2 months ago

ACHV
ACHV: Commercialization in Focus

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT 3Q:24 Operational and Financial Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported third quarter 2024 results in a November 7th press release distributed after the market's close. The company subsequently held a conference call discussing progress with the ORCA OL trial, pre-commercialization activities and the

Zacks Small Cap Research 2 months ago

ACHV
Achieve Life Sciences Inc (ACHV) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

Achieve Life Sciences Inc (ACHV) secures FDA breakthrough designation and completes key trial enrollment, while navigating financial and operational hurdles.

GuruFocus.com 2 months ago

ACHV
Achieve Life Sciences Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

Company to host conference call at 4:30 PM EST today, Thursday, November 7, 2024SEATTLE and VANCOUVER, British Columbia, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced its financial results for the third quarter of 2024 and provided an update on its cytisinicline development program. Recent Highligh

GlobeNewswire 2 months ago

ACHV
Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 7, 2024

SEATTLE and VANCOUVER, British Columbia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced it will report its third quarter 2024 financial results and provide a corporate update on the cytisinicline development program on Thursday, November 7, 2024, at 4:30 PM EST. To access the webcast, please use the

GlobeNewswire 3 months ago

ACHV
Achieve Life Sciences President and CMO, Dr. Cindy Jacobs, Speaks at FDA and NIH Smoking Cessation Public Meeting

SEATTLE and VANCOUVER, British Columbia, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, announced that Dr. Cindy Jacobs, Achieve’s President and Chief Medical Officer, presented at the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) Joint Public Meeting on “Advancing Smoking Cess

GlobeNewswire 3 months ago

ACHV
Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline

SEATTLE and VANCOUVER, British Columbia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, is pleased to announce the promotion of Ms. Jaime Xinos to Chief Commercial Officer, effective immediately. Ms. Xinos has been with Achieve Life Sciences since 2017, serving as Executive Vice President of Commercial. In her expa

GlobeNewswire 3 months ago

ACHV
Achieve Life Sciences Announces Completion of Enrollment in ORCA-OL Clinical Trial & Successful Outcome of the First Data Safety Monitoring Committee Meeting

SEATTLE and VANCOUVER, British Columbia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, announced today an update on the ORCA-OL clinical trial, evaluating long-term exposure of the novel 3 mg cytisinicline treatment dosing regimen in individuals who smoke cigarettes or vape nicotine. Enrollment for the ORCA-OL tri

GlobeNewswire 3 months ago

ACHV
Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs

SEATTLE and VANCOUVER, British Columbia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, is pleased to announce the appointment of Dr. Mark L. Rubinstein as its new Head of Medical Affairs. Dr. Rubinstein brings more than two decades of experience in clinical medicine, scientific research, and medical affairs l

GlobeNewswire 3 months ago

ACHV
ACHV: New Skipper at the Helm

By John Vandermosten, CFA NASDAQ:ACHV Achieve Life Sciences, Inc. (NASDAQ:ACHV) announced a shift in its most senior ranks with Richard Stewart reassuming his role as CEO and Thomas King, taking over as Executive Chairman. Richard Stewart had previously held the CEO role at Achieve changing the mantle of command to John Bencich in Fall of 2020. Mr. Stewart has now returned as negotiations with

Zacks Small Cap Research 4 months ago

ACHV
Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors

Richard Stewart reassumes role of Chief Executive Officer Thomas King appointed Executive Chairman of the Board of Directors SEATTLE and VANCOUVER, British Columbia, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Mr. Richard (Rick) Stewart, Achieve’s co-founder and current Executive Chairm

GlobeNewswire 5 months ago

ACHV

Performance Overview

Return	SP4P.F	S&P 500
YTD	-14.59%	+2.26%
1-Year	-32.33%	+22.65%
3-Year	-50.08%	+36.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Achieve Life Sciences, Inc. (SP4P.F)

Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory

ACHV: Long-Term Exposure Requirement Complete

Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

Should You Expect a Strong Re-rating for Achieve Life Sciences (ACHV) Post Results in Q1?

Institutional shareholders may be less affected by Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) pullback last week after a year of 0.5% returns

Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

ACHV: Commercialization in Focus

Achieve Life Sciences Inc (ACHV) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

Achieve Life Sciences Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 7, 2024

Achieve Life Sciences President and CMO, Dr. Cindy Jacobs, Speaks at FDA and NIH Smoking Cessation Public Meeting

Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline

Achieve Life Sciences Announces Completion of Enrollment in ORCA-OL Clinical Trial & Successful Outcome of the First Data Safety Monitoring Committee Meeting

Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs

ACHV: New Skipper at the Helm

Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors

Performance Overview